Reishi and Lion’s Mane Mushrooms for Epilepsy Relief

Reishi (Ganoderma lucidum) and Lion’s Mane (Hericium erinaceus) are functional mushrooms that have been studied for their potential neuroprotective, anti-inflammatory, and nervous system-supporting properties. In 2025, Realm of Caring, Unlimited Sciences, and Lily’s Lighthouse collaborated on a first-of-its-kind mixed-methods study exploring how people with epilepsy were using these mushrooms as complementary or stand-alone approaches to seizure management.

The study included 19 participants, most of whom were children represented by caregivers. Fourteen participants met criteria for drug-resistant epilepsy (DRE), meaning they had previously tried at least two anti-seizure medications without achieving adequate seizure control.

Researchers used a mixed-methods design that combined surveys with structured interviews. Participants reported on:

• Seizure frequency and severity
• Quality of life
• Sleep quality
• Cognitive and developmental outcomes
• Caregiver burden
• Overall health and well-being

Researchers then analyzed both numerical survey responses and qualitative interview themes to better understand participants’ experiences.

Participants and caregivers frequently reported:

• Reduced seizure frequency
• Reduced seizure severity
• Improved cognitive functioning
• Better memory and attention
• Developmental gains in children
• Improved emotional regulation
• Increased social engagement
• Improved overall quality of life

Some participants described dramatic improvements, including seizure freedom, although these reports have not yet been verified through controlled clinical trials.

Based on participant reports, Reishi and Lion’s Mane were used for:

• Drug-resistant epilepsy (DRE)
• Seizure reduction
• Cognitive support
• Developmental support in children
• Emotional well-being
• Quality of life improvement

Many participants used the mushrooms alongside conventional anti-seizure medications rather than as replacements. Researchers note that functional mushrooms may have potential as complementary therapies, but they should not be considered established treatments for epilepsy at this time.

Key findings from the study included:

• 94.7% of participants reported a positive impact on how seizures affected their lives.

• 68.4% reported at least some reduction, or a significant reduction, in seizure frequency and/or severity.

• 84.2% reported moderate to significant overall improvement in their condition on the Patient Global Impression of Change scale.

• 57.9% reported changes in physician or hospital utilization following functional mushroom use.

• Participants reported quality-of-life scores comparable to those observed in the general population across physical, psychological, social, and environmental domains.

• Among participants with drug-resistant epilepsy, many reported meaningful reductions in seizure severity despite previous treatment failures.

Researchers also found that lower perceived stress and lower seizure severity were associated with reduced caregiver burden, suggesting that improvements in seizure management may positively affect entire families.

This study was not designed to systematically evaluate adverse effects, safety, or drug interactions.

Important limitations include:

• Small sample size (19 participants)
• No control group
• Reliance on self-reported outcomes
• Potential placebo effects
• Self-selection bias among participants already interested in functional mushrooms
• Difficulty determining whether improvements were due to mushrooms, other therapies, or multiple factors occurring simultaneously

Participants also reported challenges identifying effective dosages, highlighting the need for controlled clinical research. Researchers emphasize that these findings are preliminary and hypothesis-generating rather than conclusive evidence of efficacy.

This preliminary study suggests that Reishi and Lion’s Mane mushrooms may hold promise as complementary approaches for epilepsy, including drug-resistant epilepsy. Participants commonly reported improvements in seizure control, cognition, development, emotional well-being, and quality of life. However, the study's design does not allow researchers to determine whether the mushrooms directly caused these improvements. Larger randomized controlled trials are needed to establish efficacy, safety, dosing guidelines, and mechanisms of action before these mushrooms can be considered evidence-based epilepsy treatments.

https://www.sciencedirect.com/science/article/pii/S2950199725002629#sec0125